Identification of tofacitinib, Filgotinib and Ruxolitinib on experimental Sjögren's syndrome model in mice

Establishment and Optimization of scRNA-seq assay to find the mechanism of immune therapy against tumors

Tumor evolution inactivates microRNA machinery for immune evasion

Establishment of In vitro Human T cell Exhaustion Model to Enable High Throughput

Myeloid-dominated spontaneous tumor models as the tool for the evaluation of immune modulators

Construction of Siglec-15 knockout mouse model and validating the effect of Siglec-15 KO on T cell response

Establishment of KRAS-G12C inhibitor induced resistant tumor models enable the development of new generation KRAS-G12C inhibitors and combinatorial strategies

Establishment of KRAS G12C mutant patient-derived xenograft (PDX) models for pre-clinical evaluation of KRAS G12C targeted anticancer therapy

Validation of GVHD in mouse model for preclinical efficacy screen

Engineered cell line panel complemented with in vivo models to enable next-generation target therapy discovery in cancer

Establishment of drug induced resistant tumor models enable the development of next generation anticancer therapeutics

CRISPR library screens identify frequent cancer mutations regulating PD-1 blockade response

Outsourcing Drug Discovery And Development

Considerations for emerging biophama companies

How Diversity In Therapeutic Strategies Is Expanding The Drug Discovery Toolbox

Bifunctional Molecules: A Diverse New Modality That Unlocks New Target Classes

CRISPR Library Screen: A Powerful Tool For Identifying Novel Tumor Targets

CRISPR Cas9 library screen in primary T cells diffuse large B cell lymphoma cells to identify modulators in tumor-immune interaction

Inflammasome Activation in M2 Macrophage Restrain the Immune Supperssive Function

Validation of the Combinatorial Effect of Blinatumomab and Nivolumab in Caner Therapy

Enabling Technology for Targeted Protein Degradation

Unlocking the potential of DEL | Inspire Hit Discovery

Interview of Dr. Xuanjia Peng

Faster with high-speed fragment screening —Accelerate your drug discovery campaign

Magical Power of QM

To Empower Organic Syntheses

Drug Hunter: Discovering New Frontiers in Cancer Treatments & Beyond

Interview of Dr. Phil Jones, VP of Therapeutics Discovery

Specialty Chemistry Platform and Capabilities at WuXi AppTec RSD

Cutting-edge synthetic technology and expertise in special chemical matters

Merging a Passion for Biochemistry, Synthetic Chemistry, and Bioactive Molecules in Academia

Interview of Dr. Joseph Ready, Co-Founder, Rodeo

In vivo CRISPR Animal Models 

High efficiency genome editing service for drug discovery

Empowering Chemistry with Quantum Mechanics

WuXi’s RSD teams are applying and developing QM calculations in multiple areas for organic syntheses

Shifting the Paradigm of Resistance and Undruggables for Unmet Medical Needs in Cancer, Neuroscience, and Beyond

Interview of John Houston, Arvinas

DELopen: DNA Encoded Library (DEL) Platform Offering more than 2.8 Billion Compounds

Apply for DNA-Encoded Library compound for free

OncoWuXi Database: To Facilitate Oncology Drug Discovery and Translational Oncology

Providing a portable oncology database for selection and inquiry of 1,000+ models for cancer research

DELopen Promotes Worldwide Academic Research Using DNA-Encoded Libraries, Far More Than Just a Numbers Game

Interview of Dr. Richard Lerner